Case Study Of CY Pharmaceutical Strategic Mergers And Acquisitions En's Gene

Now,with the continuous adjustment of the global industrial structure and the acceleration of international economic integration,the new wave of mergers and acquisitions is sweeping across all kinds of enterprises in China,especially public companies.Mergers and acquisitions is not only an important method for China to complete the strategic adjustment of state-owned economy distribution and construction,but also the inevitable way for the enterprises to survive and develop under the conditions of market economy.Since 2013,the number and amount of enterprise mergers and acquisitions in China have been constantly refreshing,among which,strategic mergers and acquisitions have become the main characteristics of mergers and acquisitions.Due to the adjustment and normal management of national drug policy in recent years,the sales of Shanxi CY Pharmaceutical Group Co.,Ltd.'s main products: anti infective drugs,have been greatly affected.In 2013,the company began to march into the ranks of pregnant and infant products,at the end of 2014,CY Pharmaceutical finished strategic mergers and acquisitions of EN's Gene,the strategic mergers and acquisitions improved the core competitiveness of the enterprise and had a positive impact on performance.In the fierce market competition and the change of national policy,the way of CY Pharmaceutical carried out effective strategic mergers and acquisitions and the inspiration for pharmaceutical industry is very worthy to be studied.The thesis adopts the research methods of case analysis.The theory part expounds the related theories of strategic mergers and acquisitions,target enterprise selection,mergers and acquisitions performance and mergers and acquisitions integration.Then the thesis introduces the case of CY Pharmaceutical strategic mergers and acquisitions EN's Gene,including the introduction of the two companies and the description of the details of mergers and acquisitions.The case analysis part starts with the CY Pharmaceutical's selection of strategic mergers and acquisitions target enterprise and then analyzes it in details,afterwards,from the perspective of the strategic mergers and acquisitions on the short-term performance impact,the long-term performance impact,and the core competitiveness of CY Pharmaceutical,a comprehensive evaluation of mergers and acquisitions performance was conducted and the integration effect of mergers and acquisitions was analyzed.According to analysis,the following conclusions can be drawn: the target company selection of CY Pharmaceutical strategic mergers and acquisitions is based on enterprise development strategy;CY Pharmaceutical's strategic mergers and acquisitions performance has been increased on the whole;mergers and acquisitions integration is relatively successful.Then draws lessons from the case,through the analysis,it can be concluded that the strategic mergers and acquisitions of pharmaceutical enterprises must be clear about the strategic target and the target company's advantages,focus on the financial and non-financial information of the target enterprise,take care to pay the premium of mergers and acquisitions,and pay attention to the importance of integration after mergers and acquisitions.Finally,the thesis is summarized,and discusses the shortcomings and prospects.The research of this thesis will help pharmaceutical enterprises to carry out effective strategic mergers and acquisitions in the future,decrease unnecessary losses,and boost the continuous development of enterprises.